International Lectures
National Lectures
International Lectures
Nov 2021: European Society of Medicine, “IgM deficiency in autoimmune diseases, long-term follow-up” (Vienna, Austria)
Mar 2020: Russian Federation Society for Dermatology, “Biologics in Treating Blistering Diseases.” (Moscow, Russia)
Jun 2019: International Association for Dental Research, “Pemphigus and pemphigoid: Autoimmune diseases affecting the oral cavity”
(Vancouver, BC, Canada)
Jan 2019: DERMACON 2019: “Immunosuppresants in blistering diseases”, “Judicious use of immunosuppresants and immunomodulators”, “Reversing autoimmunity” (Bangalore, India)
Nov 2018: CUTICON 2018 “Pre-conference CME on immunobullous disorders”, “Bullous pemphigoid: practical approach to diagnosis and management”, “Rituximab in PV: Limitation of RA Protocol and its lack of efficacy as first-line therapy” (Nagpur, India)
Nov 2018: 6th Continental Congress, Taiwanese Dermatological Association/ISD “Recent Advances in Autoimmune Blistering Diseases”, “Biologic Agents in Blistering Diseases” (Taipei, Taiwan)
Aug 2018: 2nd World Congress on Pharmacology & Toxicology, “Combination of rituximab and intravenous immunoglobulin used as first-line therapy produces 10-year remissions” (Rome, Italy)
May 2018: International Congress on Autoimmunity, Chairman of session on “Skin and Autoimmunity” Lecture on: “Laminin 332 pemphigoid and malignancy” (Lisbon, Portugal)
Jan 2018: IADVL/DERMACON 2018, Rituximab in Pemphigus (Kochin, India)
Oct 2017: Lecture at Department of Dermatology and Venereology: A. Aliyev Azerbaijan State Advanced Training Institute for Doctors, “Principles of management of autoimmune blistering diseases”, Workshop: “Autoimmune blistering diseases” (Baku, Azerbaijan)
Oct 2017: ISD Regional Meeting, “Can autoimmunity be reversed?” (Sarajevo, Bosnia & Herzegovina)
Jul 2017: CME on Pemphigus and Pemphigoid “Rush towards rituximab” (Pune, India)
Jun 2017: Scientific Conference of the International Pemphigus and Pemphigoid Foundation, “The future role of IVIg in the treatment of pemphigus” (Lübeck, Germany)
Oct 2016: Asian Dermatological Congress, “Resistant pemphigus -reasons and remedies” (Mumbai, India)
National Lectures
Feb 2021: Sonoma Eye Conference (virtual)“IgM deficiency in autoimmune blistering diseases” (Sonoma, CA)
Mar 2019: Sonoma Eye, “Newer Subsets of Mucous Membrane Pemphigoid” (Sonoma, CA)
Sep 2018: Massachusetts Academy of Dermatology Annual Meeting, “Topical Care in Blistering Diseases”, “Biologics in Blistering Diseases” (Newport, RI)
Mar 2018: Sonoma Eye, “Can autoimmunity be reversed?” (Sonoma, CA)
Feb 2018: American Academy of Dermatology Annual Meeting, “The case for using IVIg with rituximab for autoimmune bullous diseases” (San Diego, CA)
Oct 2017: New York Medical College, Use of Biologics in treating blistering diseases (Valhalla, NY/Metropolitan Hospital)
Sept 2017: International Pemphigus & Pemphigoid Foundation, “Introduction to pemphigoid”, “Below the belt”
(Newport Beach, CA)
Sep 2016: International Pemphigus & Pemphigoid Foundation Conference, Workshops: “Below the belt,” “IVIg” and “Pemphigoid Q&A” (Austin, TX)
May 2016: Tufts University of Medicine Grand Rounds, Presentation of seven patients. “Combination of IVIg and RTX in Treating Pemphigus & Pemphigoid” (Boston, MA)
May 2016: Baylor College of Medicine / UT Houston Department of Dermatology, “Benefits of Combination of IVIg and RTX in Treating Autoimmune Blistering Diseases” (Houston, TX)
May 2016: Houston Dermatological Society Meeting, “Use of Biological Agents in Treating Autoimmune Blistering Diseases” (Houston, TX)
Mar 2016: 74th American Academy of Dermatology, “Recent Advances in Bullous Diseases,” “IVIg Uses in Autoimmune Bullous Diseases” (Washington, DC)
International Lectures
Sep 2016: Pathogenesis of Pemphigus & Pemphigoid Meeting, Two posters presented (Munich, Germany)
Apr 2016: 10th International Congress on Autoimmunity, Chair session “Autoimmunity in Dermatology”, “Benefit of the combination of IVIg and rituximab in treating blistering diseases.” (Leipzig, Germany)
Apr 2016 International Society for Dermatology/Dubai Derma Joint Meeting, Preconference Course “Vesiculobullous Diseases”, “Benefits of combination of IVIg and rituximab in treating autoimmune blistering diseases” (Dubai, UAE)
Mar 2016: 1st International Dermatology and Cosmetology Congress, “Evidence-based Treatment in Pemphigus Vulgaris”, “Rituximab Uses in Dermatology,” “IVIg Uses in Autoimmune Bullous Diseases” (Istanbul, Turkey)
Jan 2016: Dubai Academy of Dermatology, “Autoimmune Progesterone Dermatitis,” “Updates on Pemphigus,” “Updates on Pemphigoid” (Dubai, UAE)
May 2015: Euro-Asian Dermatology Congress, Lectures: Principles of Clinical Management of Pemphigus Vulgaris, Autoimmune Blistering Diseases Workshop, Case Studies (Astana, Kazakhstan)
April, 2015: Bioderma Scientific Meeting – Lecture on Update in Pemphigus and Pemphigoid, Principles of management of autoimmune blistering diseases (Dubai, UAE)
April 2015: Tunisian Society of Dermatology &Venereology–National Congress of Dermatology. Lectures: “Principles of Management of autoimmune blistering diseases,” “Long-term remission produced by IVIg,” “Importance and need for appropriate topical care.” (Tunis, Tunisia)
Oct 2014: 1st International Transcaucus Congress on Photodermatology & Skin Cancer: “Autoimmmune bullous disease workshop” (Tbilisi, Georgia)
Sept 2014: 3rd Eastern Asia Dermatology Congress (EADC) – Plenary lecturer: “Role of biologics in blistering diseases” (Jeju, S. Korean)
Sept 2014: 10th International Conference of Jordanian Society of Dermatology – “Comprehensive approach to diagnosis and treatment of pemphigus and pemphigoid,” “Road to Rituximab,” “Subsets of mucous membrane pemphigoid – clinical importance and relationship to cancer” (Amman, Jordan)
Aug 2014: Dermatology Society of South Africa Annual Congress, “Clinical features of diagnostic workup in patients with autoimmune blistering diseases,” “Blistering diseases below the belt,” “The role and use of biological agents in blistering diseases.” (Johannesburg, South Africa)
National Lectures
Feb 2016: KabaFusion Invited Lecture, “Optimizing the use of IVIg in autoimmune blistering diseases.” (Edison, NJ)
March 2015: 73rd American Academy of Dermatology, Long-term remission in treating pemphigus (San Francisco, CA)
Apr 2014: International Pemphigus and Pemphigoid Foundation Meeting, “Introduction to autoimmune blistering diseases” and “Treatment side effects” (Chicago, IL)
Apr 2014: World Workshop Oral Medicine, Consultant (Orlando, FL)
Mar 2014: American Academy of Dermatology Annual Meeting (Denver, CO)
Mar 2014: Medical Dermatology Society Annual Meeting, IVIg: Indications and side effects (Denver, CO)
Oct 2013: Massachusetts Academy of Dermatology Annual Meeting, “Comprehensive approach to diagnosis and treatment management of pemphigus and pemphigoid” (Woodstock, VT)
May 2013: IMANE – Spring Symposium – “End of Life Care” Risk Mgmt CME required, Waltham MA, Mass Medical Society, in Association w/Emerson Hospital (Waltham, MA)
May 2013: International Pemphigus and Pemphigoid Foundation Meeting, “Focus on Therapy of Bullous Disease” (San Francisco, CA)
Mar 2013: American Academy of Dermatology Annual Meeting, Newer Therapies—indications and adverse events (Miami, FL)
Feb 2013: Medical Dermatology Society Annual Meeting, Rituximab in pemphigus vulgaris (Miami, FL)
Dec 2012: Mt. Sinai Winter Symposium, “Blistering Diseases – Road to Rituximab” (New York, NY)
May 2012: IPPF Meeting, Plenary Session: “Use of IVIg and Rituximab in Autoimmune Blistering Diseases.” (Boston, MA)
May 2012: International Pemphigus and Pemphigoid Foundation Meeting, Program Director and Program Chair. (Boston, MA)